Articles tagged with Blood Cancer
Researchers have discovered a new mechanism by which an existing cancer drug can block the loss of BCMA molecules on cancer cells, allowing CAR T cell therapy to become effective again in some patients. The study shows that carfilzomib can prevent the degradation of BCMA and restore its presence on the surface of malignant plasma cells.
A global study found that ropeginterferon alfa-2b controls essential thrombocythemia effectively, improves symptoms and reduces serious complications in patients who can't use hydroxyurea. The therapy is expected to be approved for treatment of high-risk blood cancer.
Predictions for lung cancer death rates among EU and UK women indicate stabilization of mortality rates at 12.5 deaths per 100,000 in 2026. Lung cancer remains the leading cause of cancer death for both sexes in the EU, with mortality rates continuing to decline among men.
New studies from Sylvester reveal that 40% of cancers are preventable and that lifestyle interventions can play a crucial role in cancer treatment. Researchers also discovered PFAS on firefighter gear, which may limit exposure to hazardous chemicals linked to cancer.
Researchers at MD Anderson have made significant advancements in cancer treatment, demonstrating the effectiveness of immunotherapy before and after surgery in improving lung cancer patient outcomes. Additionally, a new study shows promise in using CAR T cell therapy to treat large B-cell lymphoma, reducing relapse rates.
CORAL accurately predicts genetic subtypes and patient outcomes in multiple myeloma without costly genomic tests. The technology could be applied to other cancers, opening the door to personalized, faster and widely accessible cancer care.
A virtual diet and exercise program has been shown to reduce treatment side effects and increase treatment retention, according to a Sylvester study presented at ASH 2025. Lifestyle interventions can also help patients with blood cancers such as MDS and large B-cell lymphoma receive more effective and less toxic treatments.
A new study by University of Maryland researchers found that Black patients with aggressive leukemia have lower survival rates and are more likely to die from the disease compared to white patients. The disparity is attributed to younger age at diagnosis rather than genetic differences, according to Dr. Shella Saint Fleur-Lominy.
Dr Aldona Mzyk's project uses quantum sensors to track how immune cells interact with tumours, enabling the development of improved patient-tailored cancer therapies and earlier diagnosis tools. The research aims to overcome current cancer immunotherapies' failure in solid tumours by controlling metabolic changes.
Researchers have found that CAR T-cell therapy with cilta-cel leads to higher rates of complete remission and longer progression-free survival compared to ide-cel. Treatment success is linked to factors such as tumour burden, T-cell fitness, and systemic inflammation.
A study published in JAMA Network Open found that older adults with chronic kidney disease or cerebrovascular disease are at double the risk for developing neuroinvasive West Nile virus infection, which can lead to paralysis and death. The study identified several risk factors, including male sex, immune suppressants, and multiple scle...
A new Mayo Clinic study found that an off-the-shelf dual-antibody therapy generates deep and durable responses in extramedullary multiple myeloma. In a trial of 90 patients, 79% responded to treatment, with nearly two-thirds maintaining disease control at one year.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center have identified a small molecule that can inhibit cancer-driving protein IGF2BP3, slowing leukemia growth and triggering cancer cell death. The discovery could lead to new treatments for leukemia and other hard-to-treat cancers.
A new clinical trial suggests that combining bispecific antibodies and antibody-drug conjugates with CAR T-cell therapy may significantly enhance one-year progression-free survival for people with aggressive lymphoma. The study found that 90% of patients were in complete remission at day 90, and about 80% remained in remission at one y...
A new national study reveals a strong link between Agent Orange exposure and the risk of developing myelodysplastic syndrome, with exposed veterans diagnosed at younger ages and experiencing more aggressive disease. The study found that those with MDS were nearly twice as likely to see their disease progress within two years after diag...
Researchers from City of Hope presented results on novel cellular and immunotherapies, treatment strategies for hard-to-treat blood cancers, and a first-in-human trial for GVHD. The studies showed promising outcomes, including higher event-free survival rates and fewer side effects.
A new study finds that most patients with a rare and aggressive form of large B-cell lymphoma can safely receive a less toxic treatment than intensive chemotherapy. The R-CHOP regimen has shown strong four-year survival rates for THRLBCL patients without significant side effects.
A new computational tool has discovered a previously unknown protein pathway that triggers the death of blood cancer cells when blocked. This finding could lead to new treatments and improved survival rates for patients with aggressive acute myeloid leukaemia (AML).
A new study presented at ASH 2025 suggests that a virtual program focusing on diet and exercise can help reduce the severity of side effects associated with lymphoma treatment. The program, LIFE-L, showed significant improvements in symptoms such as anxiety, depression, pain, fatigue, and constipation among participants.
Researchers have found that patients with blood cancers can safely receive stem cell transplants from mismatched, unrelated donors using a protective regimen. The study's findings could make transplants accessible to nearly all patients with blood cancers, regardless of ancestry.
A clinical trial found that linvoseltamab, a bispecific antibody, eliminated 90% of tumor cells in patients with residual disease. The treatment allows patients to bypass high-dose chemotherapy and bone marrow transplants, potentially improving long-term outcomes.
The updated 2025 American Society of Hematology guidelines recommend that most older adults with acute myeloid leukemia (AML) receive treatment, including gentler chemotherapy regimens and targeted therapies. The guidelines aim to provide more personalized and effective care for this patient population.
Researchers from Penn Medicine will present data on latest advances in blood cancer and classical hematology research at the 67th American Society of Hematology Annual Meeting. The presentation includes updates on preclinical, clinical, and population-based research, as well as a multicenter Phase II study and a randomized phase III tr...
A new study from Cincinnati Children's reveals how Fanconi anemia disrupts energy pathways and affects glucose metabolism, paving the way for targeted dietary interventions to improve health and reduce cancer risk. The research uses isotope tracing metabolomics to track nutrient metabolism in people with FA.
A new protocol for Treg expansion uses targeted immunotherapy to reduce transplant complications, boosting survival rates while preserving anti-cancer immunity. The protocol, led by Robert Levy, uses TL1A-Ig fusion protein and low-dose IL-2 to stimulate specific receptors on Tregs, promoting a safer environment for stem cell transplants.
Researchers at the University of Virginia Health System have developed a new treatment for acute myeloid leukemia, a deadly form of blood cancer. The FDA-approved medication works by disrupting cellular protein interactions that drive leukemia cell growth and survival, offering patients a potential cure.
A recent study found that young donors (18-35 years old) with minor HLA differences can provide better survival rates and outcomes compared to older sibling donors. Additionally, gender and CMV status also play a role in donor selection.
Researchers have developed a system called CytoDiffusion that uses generative AI to study the shape and structure of blood cells. The system can accurately identify normal blood cell appearances and spot unusual or rare cells that may indicate disease, outperforming existing systems in tests.
Researchers have made significant advancements in diagnosing acute myeloid leukemia (AML), a common and aggressive form of blood cancer. Genetic testing can now predict relapse after stem cell transplant and detect hidden gene fusions that were previously undetectable.
Researchers from the University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center will present their work on various hematological conditions at ASH 2025. These posters highlight recent findings in fields such as von Willebrand disease, multiple myeloma, and acute myeloid leukemia.
Researchers identified a new subtype of T-cells that do not respond to current treatments and could impact clinical care. A genetic marker, ZBTB16, was found to be switched on in these cells, which can be used to identify them.
City of Hope experts will highlight advances in blood cancer research, cellular therapies, and precision medicine at the 2025 American Society of Hematology Annual Meeting and Exposition. The meeting will feature over 105 sessions covering topics such as CAR T cell therapy, transplant innovations, and precision medicine.
Multiple Sylvester physicians presented their research on various hematological cancers, including lymphoma and myeloma. The studies showcased promising results for treatments such as CAR-T therapy and immunotherapy combinations.
The DEFEND study aims to assess whether virtual exercise sessions can be successfully delivered to patients with cancer receiving chemotherapy. Researchers will evaluate the impact on physical function, fatigue, and disability.
Researchers at MD Anderson Cancer Center identified distinct cellular microenvironments in diffuse large B-cell lymphoma tumors, providing a framework to develop therapies that engage the patient's immune system. Additionally, a study found widespread misbeliefs about the cancer risks of alcohol among Americans, highlighting the need f...
Researchers developed a computational platform to design synthetic protein receptors that can detect tumor signals and boost T cell activity. The new receptors, called T-SenSERs, showed improved tumor control and longer survival in mouse models of lung cancer and multiple myeloma.
BH3 mimetics demonstrate potent anti-cancer activity by targeting pro-survival BCL-2 proteins, effectively eradicating leukaemia cells with complex mutations. The review highlights several important findings about BH3 mimetics and their role in treating acute myeloid leukaemia.
Recent studies from Sylvester have uncovered links between breast cancer, Superfund sites and social adversity. Researchers are also exploring the use of artificial intelligence (AI) in interpreting mammograms more accurately.
Researchers at MD Anderson have discovered a previously unknown mechanism that explains how bacteria can drive treatment resistance in patients with oral and colorectal cancer. The study also identifies a new biomarker for improved immunotherapy responses in solid tumors.
The Josep Carreras Institute is pioneering Spatial Transcriptomics to understand tumor structure at the cellular level. The institute's guidance on this methodology offers practical solutions for improving reproducibility and clinical application.
Scientists at Institut Pasteur and Inserm developed a triple-therapy approach to treat blood cancers like lymphomas and leukemias. They induced necroptosis in malignant B cells, which activates the immune system to eliminate tumor cells.
The ASAP study found that transplantation as soon as possible does not provide a survival advantage over remission induction, but reduces hospital stays and chemotherapy exposure. Age and AML genetics are the most important risk factors influencing survival.
A study of 9/11 first responders found mutations in blood-forming cells may explain increased leukemia risk, suggesting a targeted intervention against environmental toxins. The research also identified IL1RAP as a protein culprit, which could be used to prevent or treat blood cancers in individuals exposed to similar disasters.
A groundbreaking study enrolls 465 AYA cancer patients to test if chatbot technology and digital education tools increase uptake of genetic counseling and improve patient outcomes. The trial aims to address longstanding gaps in genetic services for AYAs aged 18-39, who often receive care with limited access to genetic specialists.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center identify IGF2BP3 as a master switch linking cancer metabolism and RNA regulation in leukemia cells. The protein shifts energy breakdown and RNA modifications to support cell survival and multiplication.
Researchers identified genetic modifications that can improve the efficacy of chimeric antigen receptor (CAR)-T cell treatment for multiple myeloma and other cancers. The study used CRISPR screening to pinpoint genes that influenced T cell function and survival in culture and in a preclinical model of multiple myeloma.
Duke University researchers discovered that inhibiting an enzyme involved in iron regulation makes cancer cells vulnerable to cell death. By targeting STK17B kinase, they reactivated ferroptosis and increased the effectiveness of conventional therapies against multiple myeloma.
A study published in The New England Journal of Medicine found that nearly 4 million children and adolescents were at higher risk of developing blood cancers due to radiation exposure from medical imaging. The researchers estimated that up to 10% of pediatric blood and bone marrow cancers may be attributable to radiation exposure.
The AACR Cancer Progress Report highlights the impact of federal investments on cancer research, with FDA approval of 20 new cancer drugs and improved survival rates. However, challenges such as early-onset cancers and instability at NIH threaten ongoing progress.
A consortium led by the University of Southampton aims to advance cutting-edge treatments for lung cancer, blood cancers, and chronic inflammation. The ON-TRACT project will train researchers in academic, industrial, and clinical settings to develop safer and more effective treatments.
Oral mucositis increases infection risks in stem cell transplant patients by nearly four times, according to new research. A superior AI tool has been introduced to accurately predict these risks, enabling targeted oral care before transplants and reducing complications.
A recent study sequenced human cancers and found little evidence of microbial DNA sequences, contradicting earlier claims. However, microbes linked to human cancer were detected, including HPV, Helicobacter pylori, and Fusobacterium nucleatum.
A new study assesses ChatGPT 3.5's performance on hematology-oncology tasks, revealing its strengths and limitations in providing accurate information for patients. The study highlights the importance of physician oversight when using AI-generated medical information.
The foundation provides $300,000 total funding over four years to investigate cancer causes, mechanisms, therapies, and prevention. This support fosters interdisciplinary research and encourages innovative projects that push boundaries and make breakthroughs.
Researchers at WashU Medicine found that clonal hematopoiesis, a condition caused by mutated blood stem cells, is more common among individuals with inherited mutations that increase cancer risk. Those with inherited mutations had a higher risk of developing blood cancer if their stem cell clones acquired additional harmful mutations.
A new study reveals that DNA damage in multiple myeloma initiates 2-4 decades before diagnosis, with key genomic events including IGH translocation and chr 1q gain. These findings may lead to new precision medicine treatment strategies for patients.
A young investigator has received prestigious grants to continue research on using RAS inhibitors to treat blood cancers. The studies aim to understand the role of RAS mutations in acute myeloid leukemia and explore potential combination therapies.
Scientists have developed a monoclonal antibody to combat life-threatening inflammatory diseases like sepsis and ARDS. The antibody shows promise in blocking the immune system's hyperactive response and restoring healthy function without unwanted side effects.
The DKMS John Hansen Research Grant is supporting innovative research projects in blood cancer therapy, aiming to improve treatment outcomes. The grant, worth almost €1 million, will support young scientists with a focus on transplant immunology and novel diagnostic and therapeutic strategies.
The Pew Charitable Trusts has announced the 2025 class of the Pew-Stewart Scholars Program for Cancer Research, supporting five early-career scientists in innovative research projects. The recipients will explore pressing topics such as complex cancer mechanisms and new drug targets.